Target-oriented pharmacogenetic studies offer a unique opportunity to understand variations in response to highly selective protein therapeutics. Krejsa and colleagues review recent pharmacogenetic investigations of protein drugs, and present a case for initiating such studies during early clinical development.
- Cecile Krejsa
- Mark Rogge
- Wolfgang Sadee
